Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Taiho’s TS-1 Non-Inferior to UFT/LV in Resected Colon Cancer Patients: PIII Study
June 7, 2013
- Nichi-Iko Announces Launching of Authorized Generic of Allegra in June; Is Late Launch Part of Sanofi’s Carefully Worked-out Strategy?
June 7, 2013
- Use of Contract MRs on the Rise among Smaller Drug Makers; JCSOA’s Goal of “5,000 CMRs by 2015” May Be Realistic
June 7, 2013
- Zeria, Astellas Launch World’s First FD Treatment
June 6, 2013
- DSP Completes Construction of New Chemical Research Facility in Osaka
June 6, 2013
- AZ Decides Not to Proceed with Regulatory Filings for Novel Oral RA Treatment Fostamatinib
June 6, 2013
- Nihon Chouzai to Increase Its Subsidiary’s Generic Production Capacity
June 5, 2013
- Takeda Unveils Interim Data from ADCETRIS PI Study in Pediatric Patients
June 5, 2013
- Fujifilm, Dr. Reddy’s Terminate Plan for Joint Venture for Generics
June 5, 2013
- Novartis Pharma to Cut Pay of 9 Top Officials and Suspend Promotion of Ethical Drugs for 5 Days Over Diovan Scandal
June 5, 2013
- Nippon Chemiphar to Outsource Production to Vietnam Next Spring
June 5, 2013
- BMKK, Ono Start Copromotion of Orencia following Lifting of All-Case Surveillance
June 5, 2013
- Four Drug Makers File Their Anticancer Drugs for FOLFIRINOX Therapy for Pancreatic Cancer
June 4, 2013
- Japan Pharma Leaders: Drug Development via GHIT Fund Hoped to Fuel Economic Growth in Developing World
June 4, 2013
- Fujifilm Initiates PI Study of MDS Treatment FF-10501 in Japan
June 4, 2013
- AZ to Assess Possibility of EGFR Mutation Testing via Blood in Japan-Europe Study
June 3, 2013
- Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
- EvaluatePharma Estimates Orphan Drug Market Will Grow to US$127 Billion by 2018
May 31, 2013
- Kyowa Kirin Launches Parkinson’s Disease Treatment Nouriast in Japan
May 31, 2013
- Sawai Aims for All Its New MRs to Pass MR Examination for Fifth Year in a Row
May 31, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…